3 citations
,
April 2025 in “International Journal of Pharmaceutics” Nanocrystals improve alopecia areata treatment by better targeting hair follicles.
6 citations
,
June 2008 in “Journal of the European Academy of Dermatology and Venereology” A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
June 2023 in “CRC Press eBooks” Acorus calamus has potential health benefits but needs more safety research.
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
July 2000 in “Hair transplant forum international” 2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
17 citations
,
June 2017 in “Journal of pharmaceutical sciences” Researchers developed a nanomedicine for acne treatment that delivers medication with less irritation and is non-irritating for oily skin.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
October 2025 in “Influenza and Other Respiratory Viruses” Certain alkaloids could help create new coronavirus drugs.
15 citations
,
December 2016 in “Advanced Pharmaceutical Bulletin” The new cream with N-acetyl glucosamine didn't change skin color after 8 weeks.
2 citations
,
October 2004 in “Organic Process Research & Development” The document reviews 20 U.S. patents from July and August 2004 about new drug forms, cancer treatments, aroma chemicals, statin drugs, and various chemical production methods.
18 citations
,
May 2024 in “Pharmaceutics” Improved delivery systems can enhance oleanolic acid's effectiveness in treating various conditions.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
1′S-1′-Acetoxychavicol acetate may help treat hair loss by reducing oxidative stress.
3 citations
,
September 2016 in “Natural Product Communications” Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.
April 2026 in “SSRN Electronic Journal” 88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” 2 citations
,
September 2024 in “Journal of the American Academy of Dermatology”
10 citations
,
May 2016 in “Polymer” New nanocarriers improve skin drug delivery with low toxicity at certain concentrations.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.